<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutr J</journal-id><journal-id journal-id-type="iso-abbrev">Nutr J</journal-id><journal-title-group><journal-title>Nutrition Journal</journal-title></journal-title-group><issn pub-type="epub">1475-2891</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25577201</article-id><article-id pub-id-type="pmc">4326402</article-id><article-id pub-id-type="publisher-id">864</article-id><article-id pub-id-type="doi">10.1186/1475-2891-14-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Impact of weight loss diet associated with flaxseed on inflammatory markers in men with cardiovascular risk factors: a clinical study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cassani</surname><given-names>Roberta Soares Lara</given-names></name><address><email>rcassani@terra.com.br</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Fassini</surname><given-names>Priscila Giacomo</given-names></name><address><email>priscilafassini@usp.br</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Silvah</surname><given-names>Jose Henrique</given-names></name><address><email>ozeenrique@gmail.com</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Lima</surname><given-names>Cristiane Maria M&#x000e1;rtires</given-names></name><address><email>cristiane.martires@gmail.com</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Marchini</surname><given-names>J&#x000fa;lio S&#x000e9;rgio</given-names></name><address><email>jsmarchi@fmrp.usp.br</email></address><xref ref-type="aff" rid="Aff7"/></contrib><aff id="Aff6"><label/>Institute of Nutrition. Itu, S&#x000e3;o Paulo, Brazil </aff><aff id="Aff7"><label/>Department of Medicine, Division of Medical Nutrition, Ribeir&#x000e3;o Preto Medical School, University of S&#x000e3;o Paulo, Avenida Bandeirantes, 3900 Bairro Monte Alegre, CEP: 14049-900 Ribeir&#x000e3;o Preto S&#x000e3;o Paulo, Brazil </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>1</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>14</volume><elocation-id>5</elocation-id><history><date date-type="received"><day>9</day><month>9</month><year>2014</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Cassani et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Flaxseed has received attention for its anti-inflammatory and antioxidant role. The present study hypothesizes if flaxseed added to a weight loss diet could improve the lipid and metabolic profiles and decrease risk factors related to cardiovascular disease.</p></sec><sec><title>Methods</title><p>In a prospective, single blinded 42 days protocol, subjects were allocated into two groups with low carbohydrates intake: G<sub>riceLC</sub> (35% of carbohydrate and 60g of raw rice powder per day) and G<sub>flaxLC</sub> (32% of carbohydrate and 60g of flaxseed powder per day). Blood pressure, anthropometric measures and serum levels of isoprostane, C-reactive protein, Tumor Necrosis Factor-alpha, glucose, lipidic profile, uric acid, adiponectin, leptin and insulin were measured at baseline and at the end of interventions. Serum and urinary enterodiol and enterolactione were also measured.</p></sec><sec><title>Results</title><p>A total of 27 men with cardiovascular risk factors were evaluated, with mean age of 33&#x02009;&#x000b1;&#x02009;10 years to G<sub>riceLC</sub> and 40&#x02009;&#x000b1;&#x02009;9 years to G<sub>flaxLC</sub>. Both groups experienced weight loss and systolic blood pressure reduction. A decrease in inflammatory markers (CRP and TNF-&#x003b1;) was observed after flaxseed intake (mean decrease of 25% and 46% for G<sub>flaxLC</sub> respectively). All groups also showed improvement in levels of total cholesterol, LDL-c, uric acid and adiponectin. Only G<sub>flaxLC</sub> group showed a decrease in triglyceride levels.</p></sec><sec><title>Conclusion</title><p>This study suggests that flaxseed added to a weight loss diet could be an important nutritional strategy to reduce inflammation markers such as CRP and TNF-&#x003b1;.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02132728">NCT02132728</ext-link>.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/1475-2891-14-5) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Flaxseed</kwd><kwd>Inflammation</kwd><kwd>Weight loss</kwd><kwd>Obesity</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Obesity is associated with altered inflammatory markers such as high blood levels of C-Reactive Protein (CRP) and Tumor Necrosis Factor-alpha (TNF-&#x003b1;) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>] and reduced of adiponectin [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. This can contribute to incidence of diseases once adiponectin, in high levels, has been associated with a lower risk of cardiovascular death [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p>The most common approach for treatment of obesity includes hypocaloric diets resulting in energy deficit associated with restriction of certain food groups, such as those containing high-carbohydrate [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>Additionally,a recent literature review indicates more than 1000 weight loss diets published. While some eliminate one or more groups of food, others recommend the intake of specific food, based on different effects on the metabolism [<xref ref-type="bibr" rid="CR8">8</xref>]. Thus, by adding or removing a certain food seems to be possible that weight loss diets manage inflammation, as a modifiable risk factor [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>In this setting, flaxseed is well known for its antioxidant, lipid and glycemic lowering actions [<xref ref-type="bibr" rid="CR12">12</xref>] that have been attributed to its components linolenic acid, dietary fibers, lignans and its degradation products [<xref ref-type="bibr" rid="CR13">13</xref>]. This study evaluates if flaxseed added to a weight loss diet generates improvement on nutritional and inflammatory markers.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Ethics statement</title><p>This study was approved by the Ethics Committee of Ribeir&#x000e3;o Preto Medical School of S&#x000e3;o Paulo University (number 4244/2007) and conducted according to Declaration of Helsinki. All participants provided written informed consent.</p></sec><sec id="Sec4"><title>Design of the study</title><p>A prospective single blind and interventional study in which volunteers were divided into two groups, followed for 42 days and received similar proportions of carbohydrates plus brown flaxseed or rice raw powder. Participant recruitment and follow-up occurred between March 5th and July 25th, 2007.</p></sec><sec id="Sec5"><title>Participants and study settings</title><p>Subjects were recruited from a large manufacturing company at the city of Itu, S&#x000e3;o Paulo, Brazil.</p><p>The inclusion criteria were male gender, age between 20-60 years-old and at least three of the following cardiovascular risk factors: waist circumference&#x02009;&#x02265;&#x02009;90 cm [<xref ref-type="bibr" rid="CR14">14</xref>]; Body Mass Index (BMI)&#x02009;&#x02265;&#x02009;25 kg/m<sup>2</sup>
[<xref ref-type="bibr" rid="CR15">15</xref>]; fasting total cholesterol&#x02009;&#x02265;&#x02009;200 mg/dL, low density lipoprotein cholesterol (LDL-c)&#x02009;&#x02265;&#x02009;130 mg/dL, high density lipoprotein cholesterol (HDL-c)&#x02009;&#x0003c;&#x02009;40 mg/dL, triglycerides&#x02009;&#x02265;&#x02009;150 mg/dL [<xref ref-type="bibr" rid="CR16">16</xref>]; glycemia &#x02265;100 mg/dL [<xref ref-type="bibr" rid="CR14">14</xref>]; systolic blood pressure &#x02265;140 mm/Hg and/or diastolic blood pressure&#x02009;&#x02265;&#x02009;90 mm/Hg [<xref ref-type="bibr" rid="CR17">17</xref>]. The exclusion criteria were use of lipid lowering or weight loss medication in the last three months.</p></sec><sec id="Sec6"><title>Interventions</title><p>Diet plans were provided to each group as following: G<sub>riceLC</sub> group received 35% carbohydrate, 46% fat, 19% protein and 60g of raw rice powder/day. G<sub>flaxLC</sub> group received 32% carbohydrate, 47% fat, 21% protein and 60 g of flaxseed powder/day. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> shows the nutrient composition of diets.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Nutritional composition of diet according to 24-hours food recall in both groups and times assessed</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th rowspan="2">Time</th><th colspan="2">Group</th></tr><tr><th>G
<sub>riceLC</sub> (n&#x02009;=&#x02009;13)</th><th>G
<sub>flaxLC</sub> (n&#x02009;=&#x02009;14)</th></tr></thead><tbody><tr><td rowspan="2">Energy (kcal/day)</td><td>Initial</td><td align="left">3869&#x02009;&#x000b1;&#x02009;1012*<sup><italic>a</italic></sup>
</td><td align="left">3665&#x02009;&#x000b1;&#x02009;713*<sup><italic>a</italic></sup>
</td></tr><tr><td>Final</td><td align="left">1765&#x02009;&#x000b1;&#x02009;193</td><td align="left">1578&#x02009;&#x000b1;&#x02009;213</td></tr><tr><td/><td>Mean difference</td><td>-2104&#x02009;&#x000b1;&#x02009;997</td><td>-2154&#x02009;&#x000b1;&#x02009;738</td></tr><tr><td rowspan="2">Carbohydrate (g/d)</td><td>Initial</td><td align="left">451&#x02009;&#x000b1;&#x02009;118*<sup>a</sup>
</td><td align="left">478&#x02009;&#x000b1;&#x02009;73*<sup>a</sup>
</td></tr><tr><td>Final</td><td align="left">201&#x02009;&#x000b1;&#x02009;32</td><td align="left">159&#x02009;&#x000b1;&#x02009;28</td></tr><tr><td/><td>Mean difference</td><td>-188&#x02009;&#x000b1;&#x02009;214</td><td>-318&#x02009;&#x000b1;&#x02009;76</td></tr><tr><td rowspan="2">Protein (g/d)</td><td>Initial</td><td align="left">187&#x02009;&#x000b1;&#x02009;53*<sup>a</sup>
</td><td align="left">152&#x02009;&#x000b1;&#x02009;55*<sup>a</sup>
</td></tr><tr><td>Final</td><td align="left">122&#x02009;&#x000b1;&#x02009;22</td><td align="left">118&#x02009;&#x000b1;&#x02009;23</td></tr><tr><td/><td>Mean difference</td><td>-65&#x02009;&#x000b1;&#x02009;59</td><td>-34&#x02009;&#x000b1;&#x02009;57</td></tr><tr><td rowspan="2">Fat (g/d)</td><td>Initial</td><td align="left">135&#x02009;&#x000b1;&#x02009;62*<sup>a</sup>
</td><td align="left">127&#x02009;&#x000b1;&#x02009;37*<sup>a</sup>
</td></tr><tr><td>Final</td><td align="left">54&#x02009;&#x000b1;&#x02009;15</td><td align="left">55&#x02009;&#x000b1;&#x02009;11</td></tr><tr><td/><td>Mean difference</td><td>-81&#x02009;&#x000b1;&#x02009;71</td><td>-75&#x02009;&#x000b1;&#x02009;37</td></tr><tr><td rowspan="2">MUFA (g/d)</td><td>Initial</td><td align="left">43&#x02009;&#x000b1;&#x02009;20*<sup>a</sup>
</td><td align="left">42&#x02009;&#x000b1;&#x02009;12<sup>*a</sup>
</td></tr><tr><td>Final</td><td align="left">26&#x02009;&#x000b1;&#x02009;9</td><td align="left">19&#x02009;&#x000b1;&#x02009;6</td></tr><tr><td/><td>Mean difference</td><td>-17&#x02009;&#x000b1;&#x02009;26</td><td>-20&#x02009;&#x000b1;&#x02009;17</td></tr><tr><td rowspan="2">PUFA (g/d)</td><td>Initial</td><td align="left">25&#x02009;&#x000b1;&#x02009;13*<sup>a</sup>
</td><td align="left">24&#x02009;&#x000b1;&#x02009;9</td></tr><tr><td>Final</td><td align="left">12&#x02009;&#x000b1;&#x02009;6</td><td align="left">24&#x02009;&#x000b1;&#x02009;5</td></tr><tr><td/><td>Mean difference</td><td>-6&#x02009;&#x000b1;&#x02009;14</td><td>-0.8&#x02009;&#x000b1;&#x02009;10</td></tr><tr><td rowspan="2">&#x003c9;-3 (g/d)</td><td>Initial</td><td align="left">3&#x02009;&#x000b1;&#x02009;2</td><td align="left">4&#x02009;&#x000b1;&#x02009;3*a</td></tr><tr><td>Final</td><td align="left">3&#x02009;&#x000b1;&#x02009;2</td><td align="left">14&#x02009;&#x000b1;&#x02009;2</td></tr><tr><td/><td>Mean difference</td><td>-0.3&#x02009;&#x000b1;&#x02009;2.5</td><td align="left">10&#x02009;&#x000b1;&#x02009;3**<sup><italic>b</italic></sup>
</td></tr><tr><td rowspan="2">&#x003c9;-6 (g/d)</td><td>Initial</td><td align="left">22&#x02009;&#x000b1;&#x02009;11*<sup>a</sup>
</td><td align="left">22&#x02009;&#x000b1;&#x02009;8*<sup>a</sup>
</td></tr><tr><td>Final</td><td align="left">9&#x02009;&#x000b1;&#x02009;5</td><td align="left">10&#x02009;&#x000b1;&#x02009;4</td></tr><tr><td/><td>Mean difference</td><td>-13&#x02009;&#x000b1;&#x02009;13</td><td>-12&#x02009;&#x000b1;&#x02009;9</td></tr><tr><td rowspan="2">SFA (g/d)</td><td>Initial</td><td align="left">51&#x02009;&#x000b1;&#x02009;27*<sup>a</sup>
</td><td align="left">51&#x02009;&#x000b1;&#x02009;16*<sup>a</sup>
</td></tr><tr><td>Final</td><td align="left">13&#x02009;&#x000b1;&#x02009;3</td><td align="left">12&#x02009;&#x000b1;&#x02009;3</td></tr><tr><td/><td>Mean difference</td><td>-35&#x02009;&#x000b1;&#x02009;32</td><td>-38&#x02009;&#x000b1;&#x02009;14</td></tr><tr><td rowspan="2">Dietary cholesterol (mg/d)</td><td>Initial</td><td align="left">569&#x02009;&#x000b1;&#x02009;220*<sup>a</sup>
</td><td align="left">583&#x02009;&#x000b1;&#x02009;313*<sup>a</sup>
</td></tr><tr><td>Final</td><td align="left">267&#x02009;&#x000b1;&#x02009;67</td><td align="left">248&#x02009;&#x000b1;&#x02009;59</td></tr><tr><td/><td>Mean difference</td><td>-334&#x02009;&#x000b1;&#x02009;254</td><td>-335&#x02009;&#x000b1;&#x02009;322</td></tr><tr><td rowspan="2">Total fiber (g/d)</td><td>Initial</td><td align="left">41&#x02009;&#x000b1;&#x02009;15*<sup>a</sup>
</td><td align="left">42&#x02009;&#x000b1;&#x02009;14</td></tr><tr><td>Final</td><td align="left">26&#x02009;&#x000b1;&#x02009;6</td><td align="left">41&#x02009;&#x000b1;&#x02009;5</td></tr><tr><td/><td>Mean difference</td><td>-15&#x02009;&#x000b1;&#x02009;15</td><td>-7&#x02009;&#x000b1;&#x02009;20</td></tr></tbody></table><table-wrap-foot><p>Data are expressed in mean&#x02009;&#x000b1;&#x02009;Standard Deviation. n, number of subjects; Kcal/day, kilocalorie per day; g/d, grams per day; mg/d, milligrams per day; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids &#x003c9;-3, omega 3 fatty acids, &#x003c9;-6, omega 6 fatty acids.</p><p>**Significant difference between initial and final times (p&#x02009;&#x0003c;&#x02009;0.01).</p><p>
<sup><italic>a</italic></sup>Mean-comparison t test, paired data. Comparisons between initial and final times assessed.</p><p>
<sup><italic>b</italic></sup>Two-group mean comparison t test. Comparisons between the mean differences across initial and final times assessed, in both groups.</p></table-wrap-foot></table-wrap></p><p>Flaxseed and raw rice were crushed weekly by minimal particle type mill. Also, sieves were used for optimal grinding grain with a size of 250 mm/micrometers DLF 1&#x000ae; W22060&#x000ae;, 20353836 series (Universal Buhler, CMBH, Germany) and Vibrating MAQ&#x000ae; model 2221, 10.04 series (Bertel&#x000ae; Brazil). After crushing flaxseed and raw rice, they were weighed in a semi-analytical scale, OHAUS&#x000ae; (Germany) and packed in suitable plastic bags.</p><p>The following meals were made at the company: breakfast, light meal, lunch and afternoon snack. Dinner, evening snack and weekend meals were performed at home. The addition of flaxseed or raw rice powder was made in the light meal (40 g added to milk) and lunch (20 g added to baked beans). Regarding to blinding method, only a research member who did not have access to data knew what each volunteer received, rice or flaxseed.</p></sec><sec id="Sec7"><title>Dietary assessment</title><p>Dietary intake was assessed twice by 24-hour food recall, in a week day and in a weekend day. Nutrient composition of the diets at baseline and during the nutritional intervention was performed using the Diet PRO&#x000ae; Program, version 4 (Agrom&#x000ed;dia Based Technology Company&#x000ae;, Vi&#x000e7;osa, Brazil, MG).</p></sec><sec id="Sec8"><title>Physical examination</title><p>Height and weight were measured according to institutional protocols [<xref ref-type="bibr" rid="CR18">18</xref>]. BMI was classified as suggested by World Health Organization (WHO) [<xref ref-type="bibr" rid="CR15">15</xref>]. Suprailiac, subscapular and abdominal skinfolds were evaluated using a compass Lange&#x000ae; (Beta Technology Incorporated, USA). Waist and hip circumferences were also analyzed [<xref ref-type="bibr" rid="CR19">19</xref>]. Blood pressure was measured by an automated device (OMRON&#x000ae; HEM 705-CP, Japan) following current guidelines [<xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec9"><title>Biochemical assessments</title><p>Blood was collected after 12-hour fasting for biochemical assessments: total cholesterol and fractions (LDL-c and HDL-c), triglycerides, glucose, insulin, homeostasis model assessment for &#x003b2;-cell function (HOMA-&#x003b2;) and insulin resistance (HOMA-IR), uric acid, as well as for evaluation of inflammatory markers (CRP, TNF-&#x003b1;), serum isoprostane and hormones (leptin and adiponectin).</p><p>Determination of total cholesterol, HDL-c, triglyceride, glucose and uric acid was performed by enzymatic method, with HITACHI&#x000ae; 912 - ROCHE (Japan). Reagents used were: CHOD-PAP, ROCHE (Japan) for total cholesterol and triglyceride; Bioclin K071 (Japan) for HDL-c; GOD-PAD (Roche) (Japan) for glucose and Uric Acid Plus (URICASE) (Japan) for uric acid. Friedewald equation was used to determine LDL-c [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>IMMULITE 1000&#x000ae; SYSTEMS - Siemens Medical Solutions Diagnostics (Los Angeles, USA) was used to detect insulin by chemiluminescence. HOMA indexes were obtained by equations disclosed in literature [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p>Immunoturbidimetric assay was performed with the COBAS&#x000ae; MIRAPLUS - ROCHE (USA) with 0.03 mg/L as detection limit and intra assay coefficient of variation of 10% to measure ultra-sensitive CRP. The reagent used was TURB-PCR, manufacturer ERBRAM Prods. Laboratory Ltda. (S&#x000e3;o Paulo, Brazil). TNF-&#x003b1;, leptin and adiponectin were measured by enzyme immunoassay method, using LINCOPLEX-LUMINEX&#x000ae; kits, Millipore Corporation (USA). Determination of 8-Iso-Prostaglandin F2a (serum isoprostane) was performed by enzyme immunoassay kits, ASSAY DESIGNS&#x000ae; Inc, (USA).</p><p>Serum and urinary enterolignans, enterodiol (END) and enterolactone (ENL) were assessed by high performance liquid chromatography with Shimadzu model LC 10AD&#x000ae; (Shimadzu Corporation, Japan).</p></sec><sec id="Sec10"><title>Statistical methods</title><p>Student's t-test for paired data was used for comparisons between initial (day zero) and final (day 42) assessments. The mean differences between final and initial times of data collection in both groups were compared by two-group mean comparison test (t test) or Wilcoxon rank-sum test when appropriate. When assumption of normality of data was rejected, variable was normalized after logarithmic transformation or non-parametric tests were used. The analyses were conducted with STATA/IC, version 11.2 (StataCorp LP, USA). The significance level used for the tests was 5%.</p></sec></sec><sec id="Sec11" sec-type="results"><title>Results</title><sec id="Sec12"><title>Participant flow and baseline characteristics</title><p>The selection flow of subjects was summarized in Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. From 93 employees evaluated, 27 were allocated as follow: 13 in G<sub>riceLC</sub> and 14 in G<sub>flaxLC</sub>. The mean age was 33&#x02009;&#x000b1;&#x02009;10 years to G<sub>riceLC</sub> and 40&#x02009;&#x000b1;&#x02009;9 years to G<sub>flaxLC</sub>. The baseline clinical, biochemical and dietary characteristics are shown in Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref> in the time frame marked as initial. Both groups showed a reduction of approximately 56% of energy intake compared to baseline.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Study flow chart.</bold>
</p></caption><graphic xlink:href="12937_2014_864_Fig1_HTML" id="d30e1050"/></fig></p><table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Blood pressure and anthropometric data, according to study group and time of assessment</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th colspan="2">Group</th></tr><tr><th>Variable</th><th>Time</th><th>G
<sub>riceLC</sub> (n&#x02009;=&#x02009;13)</th><th>G
<sub>flaxLC</sub> (n&#x02009;=&#x02009;14)</th></tr></thead><tbody><tr><td rowspan="2">Systolic BP</td><td>Initial</td><td align="left">134&#x02009;&#x000b1;&#x02009;9.2*</td><td align="left">139&#x02009;&#x000b1;&#x02009;20.3*</td></tr><tr><td>Final</td><td align="left">125&#x02009;&#x000b1;&#x02009;8.1</td><td align="left">127&#x02009;&#x000b1;&#x02009;17</td></tr><tr><td/><td>Mean difference</td><td>-9&#x02009;&#x000b1;&#x02009;12</td><td>-12&#x02009;&#x000b1;&#x02009;11</td></tr><tr><td rowspan="2">Diastolic BP</td><td>Initial</td><td align="left">80&#x02009;&#x000b1;&#x02009;7.7</td><td align="left">83&#x02009;&#x000b1;&#x02009;13.5</td></tr><tr><td>Final</td><td align="left">77&#x02009;&#x000b1;&#x02009;8.2</td><td align="left">81&#x02009;&#x000b1;&#x02009;8.9</td></tr><tr><td/><td>Mean difference</td><td>-3&#x02009;&#x000b1;&#x02009;10</td><td>-2&#x02009;&#x000b1;&#x02009;11</td></tr><tr><td rowspan="2">Weight (Kg)</td><td>Initial</td><td>94,9&#x02009;&#x000b1;&#x02009;11,2*</td><td align="left">96&#x02009;&#x000b1;&#x02009;14*</td></tr><tr><td>Final</td><td>88,1&#x02009;&#x000b1;&#x02009;10,2</td><td align="left">90&#x02009;&#x000b1;&#x02009;14</td></tr><tr><td/><td>Mean difference</td><td>-7&#x02009;&#x000b1;&#x02009;2</td><td>-6&#x02009;&#x000b1;&#x02009;6</td></tr><tr><td rowspan="2">BMI (kg/m<sup>2</sup>)</td><td>Initial</td><td>32,1&#x02009;&#x000b1;&#x02009;2,8*</td><td align="left">32&#x02009;&#x000b1;&#x02009;3*</td></tr><tr><td>Final</td><td>29,8&#x02009;&#x000b1;&#x02009;2,5</td><td align="left">30&#x02009;&#x000b1;&#x02009;4</td></tr><tr><td/><td>Mean difference</td><td>-2.3&#x02009;&#x000b1;&#x02009;0.7</td><td>-1.9&#x02009;&#x000b1;&#x02009;2</td></tr><tr><td rowspan="2">Waist circumference (cm)</td><td>Initial</td><td align="left">107&#x02009;&#x000b1;&#x02009;8*</td><td align="left">108&#x02009;&#x000b1;&#x02009;8*</td></tr><tr><td>Final</td><td align="left">93&#x02009;&#x000b1;&#x02009;6</td><td align="left">95&#x02009;&#x000b1;&#x02009;8</td></tr><tr><td/><td>Mean difference</td><td>-14&#x02009;&#x000b1;&#x02009;3</td><td>-13&#x02009;&#x000b1;&#x02009;4</td></tr><tr><td rowspan="2">Hip circumference (cm)</td><td>Initial</td><td align="left">108&#x02009;&#x000b1;&#x02009;7*</td><td align="left">106&#x02009;&#x000b1;&#x02009;8*</td></tr><tr><td>Final</td><td align="left">104&#x02009;&#x000b1;&#x02009;6</td><td align="left">103&#x02009;&#x000b1;&#x02009;7</td></tr><tr><td/><td>Mean difference</td><td>-4&#x02009;&#x000b1;&#x02009;2</td><td>-2&#x02009;&#x000b1;&#x02009;2*<sup><italic>b</italic></sup>
</td></tr><tr><td rowspan="2">Subscapular. skinfold (mm)</td><td>Initial</td><td align="left">41&#x02009;&#x000b1;&#x02009;13*</td><td align="left">38&#x02009;&#x000b1;&#x02009;11*</td></tr><tr><td>Final</td><td align="left">18&#x02009;&#x000b1;&#x02009;3</td><td align="left">20&#x02009;&#x000b1;&#x02009;5</td></tr><tr><td/><td>Mean difference</td><td>-23&#x02009;&#x000b1;&#x02009;11</td><td>-18&#x02009;&#x000b1;&#x02009;7</td></tr><tr><td rowspan="2">Supra iliac skinfold (mm)</td><td>Initial</td><td align="left">33&#x02009;&#x000b1;&#x02009;12*</td><td align="left">37&#x02009;&#x000b1;&#x02009;9*</td></tr><tr><td>Final</td><td>15,2&#x02009;&#x000b1;&#x02009;4</td><td align="left">16&#x02009;&#x000b1;&#x02009;4</td></tr><tr><td/><td>Mean difference</td><td>-17&#x02009;&#x000b1;&#x02009;8</td><td>-21&#x02009;&#x000b1;&#x02009;10</td></tr><tr><td rowspan="2">Abdominal skinfold (mm)</td><td>Initial</td><td align="left">65&#x02009;&#x000b1;&#x02009;5*</td><td align="left">66&#x02009;&#x000b1;&#x02009;3*</td></tr><tr><td>Final</td><td align="left">23&#x02009;&#x000b1;&#x02009;4</td><td align="left">25&#x02009;&#x000b1;&#x02009;5</td></tr><tr><td/><td>Mean difference</td><td>-42&#x02009;&#x000b1;&#x02009;4</td><td>-40&#x02009;&#x000b1;&#x02009;6</td></tr></tbody></table><table-wrap-foot><p>Data are expressed in mean&#x02009;&#x000b1;&#x02009;Standard Deviation. n, number of subjects; BP, blood pressure (mmHg); BMI, body mass index, kg/m<sup>2</sup>, kilogram per meter squared.</p><p>*Significant difference between initial and final times (p&#x02009;&#x0003c;&#x02009;0.05).</p><p>
<sup><italic>b</italic></sup>Two-group mean comparison t test. Comparisons between the mean differences across initial and final times assessed, in both groups.</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Fasting biochemical data, according to study group and time of assessment</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th rowspan="2">Time</th><th colspan="2">Group</th></tr><tr><th>G
<sub>riceLC</sub> (n&#x02009;=&#x02009;13)</th><th>G
<sub>flaxLC</sub> (n&#x02009;=&#x02009;14)</th></tr></thead><tbody><tr><td rowspan="2">Glycemia (mg/dL)</td><td>Initial</td><td align="left">98&#x02009;&#x000b1;&#x02009;16</td><td align="left">90&#x02009;&#x000b1;&#x02009;15</td></tr><tr><td>Final</td><td align="left">91&#x02009;&#x000b1;&#x02009;12</td><td align="left">88&#x02009;&#x000b1;&#x02009;10</td></tr><tr><td/><td>Mean difference</td><td>-7&#x02009;&#x000b1;&#x02009;13</td><td>-1&#x02009;&#x000b1;&#x02009;16</td></tr><tr><td rowspan="2">Total cholesterol (mg/dL)</td><td>Initial</td><td align="left">205&#x02009;&#x000b1;&#x02009;36*</td><td align="left">223&#x02009;&#x000b1;&#x02009;50*</td></tr><tr><td>Final</td><td align="left">180&#x02009;&#x000b1;&#x02009;31</td><td align="left">186&#x02009;&#x000b1;&#x02009;41</td></tr><tr><td/><td>Mean difference</td><td>-25&#x02009;&#x000b1;&#x02009;21</td><td>-37&#x02009;&#x000b1;&#x02009;37</td></tr><tr><td rowspan="2">LDL-c (mg/dL)</td><td>Initial</td><td align="left">135&#x02009;&#x000b1;&#x02009;50*</td><td align="left">151&#x02009;&#x000b1;&#x02009;59*</td></tr><tr><td>Final</td><td align="left">110&#x02009;&#x000b1;&#x02009;26</td><td align="left">116&#x02009;&#x000b1;&#x02009;37</td></tr><tr><td/><td>Mean difference</td><td>-25&#x02009;&#x000b1;&#x02009;39</td><td>-31&#x02009;&#x000b1;&#x02009;51</td></tr><tr><td rowspan="2">HDL-c (mg/dL)</td><td>Initial</td><td align="left">44&#x02009;&#x000b1;&#x02009;9</td><td align="left">42&#x02009;&#x000b1;&#x02009;5*</td></tr><tr><td>Final</td><td align="left">42&#x02009;&#x000b1;&#x02009;7</td><td align="left">38&#x02009;&#x000b1;&#x02009;4</td></tr><tr><td/><td>Mean difference</td><td>-2&#x02009;&#x000b1;&#x02009;6</td><td>-4&#x02009;&#x000b1;&#x02009;5</td></tr><tr><td rowspan="2">Triacylglycerol<sup>(&#x00026;</sup>
<sup>)</sup> (mg/dL)</td><td>Initial</td><td align="left">241&#x02009;&#x000b1;&#x02009;264</td><td align="left">215&#x02009;&#x000b1;&#x02009;110*</td></tr><tr><td>Final</td><td align="left">144&#x02009;&#x000b1;&#x02009;56</td><td align="left">153&#x02009;&#x000b1;&#x02009;83</td></tr><tr><td/><td>Mean difference</td><td>-97&#x02009;&#x000b1;&#x02009;252</td><td>-62&#x02009;&#x000b1;&#x02009;71</td></tr><tr><td rowspan="2">Uric acid (mg/dL)</td><td>Initial</td><td align="left">7&#x02009;&#x000b1;&#x02009;1*</td><td align="left">7&#x02009;&#x000b1;&#x02009;2*</td></tr><tr><td>Final</td><td align="left">6&#x02009;&#x000b1;&#x02009;1</td><td align="left">6&#x02009;&#x000b1;&#x02009;3</td></tr><tr><td/><td>Mean difference</td><td>-0.5&#x02009;&#x000b1;&#x02009;0.7</td><td>-0.7&#x02009;&#x000b1;&#x02009;0.8</td></tr><tr><td rowspan="2">Insulin<sup>(&#x00026;</sup>
<sup>)</sup> (micro IU/mL)</td><td>Initial</td><td align="left">18&#x02009;&#x000b1;&#x02009;14*</td><td align="left">12&#x02009;&#x000b1;&#x02009;8</td></tr><tr><td>Final</td><td align="left">7&#x02009;&#x000b1;&#x02009;5</td><td align="left">9&#x02009;&#x000b1;&#x02009;5</td></tr><tr><td/><td>Mean difference</td><td>-11&#x02009;&#x000b1;&#x02009;13</td><td>-3&#x02009;&#x000b1;&#x02009;8</td></tr><tr><td rowspan="2">HOMA beta<sup>(&#x00026;</sup>
<sup>)</sup>
</td><td>Initial</td><td align="left">60&#x02009;&#x000b1;&#x02009;40*</td><td align="left">49&#x02009;&#x000b1;&#x02009;55</td></tr><tr><td>Final</td><td align="left">25&#x02009;&#x000b1;&#x02009;16</td><td align="left">31&#x02009;&#x000b1;&#x02009;18</td></tr><tr><td/><td>Mean difference</td><td>-35&#x02009;&#x000b1;&#x02009;40</td><td>-18&#x02009;&#x000b1;&#x02009;54</td></tr><tr><td rowspan="2">HOMA IR<sup>(&#x00026;</sup>
<sup>)</sup>
</td><td>Initial</td><td align="left">5&#x02009;&#x000b1;&#x02009;5*</td><td align="left">3&#x02009;&#x000b1;&#x02009;1</td></tr><tr><td>Final</td><td align="left">2&#x02009;&#x000b1;&#x02009;1</td><td align="left">2&#x02009;&#x000b1;&#x02009;1</td></tr><tr><td/><td>Mean difference</td><td>-3&#x02009;&#x000b1;&#x02009;4</td><td>-1&#x02009;&#x000b1;&#x02009;1</td></tr></tbody></table><table-wrap-foot><p>Data are expressed in mean&#x02009;&#x000b1;&#x02009;Standard Deviation. n, number of subjects; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol.</p><p>*Significant difference between initial and final times (p&#x02009;&#x0003c;&#x02009;0.05).</p><p>
<sup>&#x00026;</sup>Variable analyzed with log transformation.</p></table-wrap-foot></table-wrap></sec><sec id="Sec13"><title>Blood pressure, anthropometric and biochemical data</title><p>Both groups had their anthropometric and systolic blood pressure measurements reduced (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Hip circumference reduction was greater in G<sub>riceLC</sub> group. Weight loss achieved by G<sub>riceLC</sub> and G<sub>flaxLC</sub> were 7&#x02009;&#x000b1;&#x02009;2 and 6&#x02009;&#x000b1;&#x02009;6 kg (mean&#x02009;&#x000b1;&#x02009;SD), respectively. G<sub>riceLC</sub> and G<sub>flaxLC</sub> had their levels of total cholesterol, LDL cholesterol and uric acid decreased (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). G<sub>flaxLC</sub> increased blood levels of END and ENL, as well as urinary levels of ENL. On the other hand, G<sub>riceLC</sub> reduced blood levels of END and urinary levels of ENL (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Serum and urinary levels of enterodiol and enterolactone according to group and time of assessment.</bold> (&#x025b2;) G<sub>riceLC</sub>; (&#x025cf;) G<sub>flaxLC.</sub> *significant difference between initial and final times (p&#x02009;&#x0003c;&#x02009;0,05).</p></caption><graphic xlink:href="12937_2014_864_Fig2_HTML" id="d30e1857"/></fig></p></sec><sec id="Sec14"><title>Inflammatory markers and hormones</title><p>Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> illustrates the changes in inflammatory and hormonal markers according to study group and assessment time. Levels of CRP and TNF-&#x003b1; were reduced (p&#x02009;&#x0003c;&#x02009;0.05) only in G<sub>flaxLC</sub> (mean decrease of 25% and 46% respectively) and isoprostane was reduced in both groups. Also, both groups increased levels of adiponectin (Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Serum levels of CRP, TNF-&#x003b1; and isoprostane according to group and time of assessment.</bold> (&#x025b2;) G<sub>riceLC</sub>; (&#x025cf;) G<sub>flaxLC.</sub> *significant difference between initial and final times (p&#x02009;&#x0003c;&#x02009;0,05).</p></caption><graphic xlink:href="12937_2014_864_Fig3_HTML" id="d30e1889"/></fig><fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>Leptin and adiponectin levels according to group and time of assessment.</bold> (&#x025b2;) G<sub>riceLC</sub>; (&#x025cf;) G<sub>flaxLC.</sub> *significant difference between initial and final times (p&#x02009;&#x0003c;&#x02009;0,05).</p></caption><graphic xlink:href="12937_2014_864_Fig4_HTML" id="d30e1907"/></fig></p></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p>This study shows a decrease in inflammatory markers (CRP and TNF-&#x003b1;) only in group who received flaxseed, allowing the assumption yet described in literature that anti-inflammatory and antiatherogenic activities could be attributed to components of flaxseed, such as lignans and its derivatives [<xref ref-type="bibr" rid="CR23">23</xref>]. Pan et al. showed that dietary supplementation with capsules of lignans from flaxseed (360 mg/d) for 12 weeks modulates CRP levels in type II diabetics when compared to placebo group [<xref ref-type="bibr" rid="CR24">24</xref>]. The mechanisms behind these effects could be that glycosides of lignans found in flaxseed are hydrolyzed by colon bacteria producing bioactive lignans such as enterolactone (ENL) and enterodiol (END) [<xref ref-type="bibr" rid="CR25">25</xref>]. These substances were found to protect against cardiovascular disease by decreasing inflammatory response [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Increases in blood and urinary levels of END and ENL in the present study indicate absorption of lignans (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Also, antioxidant properties of lignans not evaluated in our study, like reactive oxygen species scavenger, as well as prevention of lipid peroxidation in liver could be beneficial on human health [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p>Inflammation and elevated pro-inflammatory adipokines, such as TNF-&#x003b1; induced by activation of nuclear factor kappa B, are also associated with excess weight, especially with increased visceral fat [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Correlations have been observed between increased TNF-&#x003b1; and decreased anti-inflammatory adipokines, known as adiponectin. These interrelations contribute to long-term complications such as insulin resistance, endothelial dysfunction and atherosclerosis [<xref ref-type="bibr" rid="CR30">30</xref>]. In this trial, both groups increased adiponectin blood levels suggesting that protection from diseases could be reached by weight loss in patients with overweight and obesity.</p><p>Both groups achieved weight loss and reduction of waist circumference, as well as other anthropometric data (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), explained by lower energy intake (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR31">31</xref>]. In this matter, we strengthened that to lose weight, the total intake and negative energy balance is more important than diet composition itself [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Moreover, reduction of blood pressure was another positive impact on health observed in both groups, which can be explained by improvements on weight and central adiposity [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</p><p>Other variables, such as total cholesterol, LDL-c and uric acid also improved in groups G<sub>riceLC</sub> and G<sub>flaxLC</sub>. Reducing carbohydrate intake has been related to ameliorated biochemical and hormonal profiles, regardless weight loss [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. On the other hand, some of these benefits could be explained by addition of flaxseed, since some studies have suggested that it reduces hypercholesterolemia, hyperinsulinemia, hyperleptinemia as well as accumulation of visceral fat, specifically in the liver [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>Serum triglycerides levels only decreased in G<sub>flaxLC</sub>. A study with hypercholesterolemic rabbits that consumed crushed flaxseed also showed reduced serum levels of LDL-c and triglycerides [<xref ref-type="bibr" rid="CR36">36</xref>]. G<sub>flaxLC</sub> received greater amounts of Omega-3 (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) than G<sub>riceLC</sub> (14&#x02009;&#x000b1;&#x02009;2 versus 3&#x02009;&#x000b1;&#x02009;2 g/day, p&#x02009;&#x0003c;&#x02009;0.01) which suggests that flaxseed omega 3 fatty acids really contributes to triglyceride reduction. In the past, its been suggested that very high amounts of flaxseed oil, rich in omega 3, would be able to reduce the triglyceridemia in the same way as fish oil omega 3 [<xref ref-type="bibr" rid="CR37">37</xref>]. However, recent reviews did not find any advantage using flaxseed oil compared to fish oils, as well as another vegetal oil, in this case, olive [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. One explanation for the absence of evidence of the effect of flaxseed oil in recent papers is that omega-3 fatty acids from vegetable oils is alpha-linolenic acid (ALA), different from fish oils that have, for example, the promoters of effects, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). ALA can be converted into EPA and DHA by the human body, but only in small fractions (5%), which is why we recommend the consumption of omega-3 from animal origin [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Finally, we can not conclude that in our study, the reduction of triglycerides in G<sub>flaxLC</sub> was due to flaxseed, weight loss or reduction of carbohydrates, since due to the small size of sample, statistical significance in G<sub>riceLC</sub> was not achieved. Both groups showed significant reduction in serum isoprostane. Decrease of this biomarker of lipid peroxidation occurred in the presence of nutritional intervention, being essential calorie reduction, consumption of fibers, decrease in body weight and in central adiposity [<xref ref-type="bibr" rid="CR42">42</xref>]. This trial has some limitations including convenience sampling with a small number of subjects allocated in each group. Therefore, it is not possible warrant if the outcomes were related to weight loss, intake of carbohydrates or flaxseed or a combination of these interventions.</p></sec><sec id="Sec16" sec-type="conclusions"><title>Conclusion</title><p>Despite limitations, this study suggests that in the evaluated population, weight loss diet could be an important strategy to reduce inflammation markers such as CRP and TNF-&#x003b1;. Also, flaxseed could contribute to this outcome. Moreover, reductions observed in blood pressure and central adiposity could additionally protect against cardiovascular diseases.</p><sec id="Sec17"><title>Availability of supporting data</title><p>The data set supporting the results of this article is available as six additional material files (.xls) Additional files <xref rid="MOESM1" ref-type="media">1</xref>, <xref rid="MOESM2" ref-type="media">2</xref>, <xref rid="MOESM3" ref-type="media">3</xref>, <xref rid="MOESM4" ref-type="media">4</xref>, <xref rid="MOESM5" ref-type="media">5</xref> and <xref rid="MOESM6" ref-type="media">6</xref>.</p></sec></sec><sec id="Sec18"><title>Authors&#x02019; information</title><p>JSM is full professor of Division of Medical Nutrition at University of S&#x000e3;o Paulo.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec19"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12937_2014_864_MOESM1_ESM.xls"><caption><p>Additional file 1:
<bold>Biochemical Data: measurements of lipidic profile, uric acid, blood glucose, insulin and CRP.</bold>
(XLS 36 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12937_2014_864_MOESM2_ESM.xls"><caption><p>Additional file 2:
<bold>Anthropometric Data: weight, BMI and other anthropometric measurements.</bold>
(XLS 49 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12937_2014_864_MOESM3_ESM.xls"><caption><p>Additional file 3:
<bold>Blood pressure Data.</bold>
(XLS 38 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12937_2014_864_MOESM4_ESM.xls"><caption><p>Additional file 4:
<bold>TNF, adiponectin, leptin and isoprostane.</bold>
(XLS 44 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="12937_2014_864_MOESM5_ESM.xls"><caption><p>Additional file 5:
<bold>Blood and urinary levels of lignans.</bold>
(XLS 46 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="12937_2014_864_MOESM6_ESM.xls"><caption><p>Additional file 6:
<bold>Nutritional composition of diet.</bold>
(XLS 35 KB)</p></caption></media></supplementary-material></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>CRP</term><def><p>Protein C Reactive</p></def></def-item><def-item><term>TNF-&#x003b1;</term><def><p>Tumor Necrosis Factor Alpha</p></def></def-item><def-item><term>BMI</term><def><p>Body Mass Index</p></def></def-item><def-item><term>LDL-c</term><def><p>Low density lipoprotein cholesterol</p></def></def-item><def-item><term>HDL-c</term><def><p>High density lipoprotein cholesterol</p></def></def-item><def-item><term>HOMA-&#x003b2;</term><def><p>Homeostasis model assessment for &#x003b2;-cell function</p></def></def-item><def-item><term>HOMA-IR</term><def><p>Insulin resistance</p></def></def-item><def-item><term>END</term><def><p>Enterodiol</p></def></def-item><def-item><term>ENL</term><def><p>Enterolactone</p></def></def-item><def-item><term>ALA</term><def><p>Alpha-linolenic acid</p></def></def-item><def-item><term>EPA</term><def><p>Eicosapentaenoic acid</p></def></def-item><def-item><term>DHA</term><def><p>Docosahexaenoic acid.</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>Designed the experiments: RSLC and JSM. Conducted the research: RSLC. Analyzed the data and wrote the paper: RSLC, PGF, JHS and JSM. Reviewed the paper: RSLC, PGF, JHS, CMML and JSM. JSM had primary responsibility for the final content. All the authors read and approved the final manuscript.</p></fn></fn-group><ack><p>This study was partially financed by CNPq grant (304127/2009-4) intended to JSM and also by FAEPA &#x02013; Funda&#x000e7;&#x000e3;o de Apoio ao Ensino, Pesquisa e Assist&#x000ea;ncia do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina de Ribeir&#x000e3;o Preto/University of S&#x000e3;o Paulo. PGF, JHS and CMML received scholarships 2012/22543-3, 2012/21579-4 and 2012/21626-2, respectively from FAPESP - Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa de S&#x000e3;o Paulo. CNPq, FAEPA and FAPESP are government agencies that provide financial resources, but generated no influences in the study.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><article-title>Immune mechanisms in atherosclerosis</article-title><source>Arterioscl Throm Vas</source><year>2001</year><volume>21</volume><fpage>1876</fpage><lpage>1890</lpage><pub-id pub-id-type="doi">10.1161/hq1201.100220</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couillard</surname><given-names>C</given-names></name><name><surname>Ruel</surname><given-names>G</given-names></name><name><surname>Archer</surname><given-names>WR</given-names></name><name><surname>Pomerleau</surname><given-names>S</given-names></name><name><surname>Bergeron</surname><given-names>J</given-names></name><name><surname>Couture</surname><given-names>P</given-names></name><name><surname>Lamarche</surname><given-names>B</given-names></name><name><surname>Bergeron</surname><given-names>N</given-names></name></person-group><article-title>Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity</article-title><source>J Clin Endocr Metab</source><year>2005</year><volume>90</volume><fpage>6454</fpage><lpage>6459</lpage><pub-id pub-id-type="doi">10.1210/jc.2004-2438</pub-id><pub-id pub-id-type="pmid">16189262</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paschos</surname><given-names>G</given-names></name><name><surname>Zampelas</surname><given-names>A</given-names></name><name><surname>Panagiotakos</surname><given-names>DB</given-names></name><name><surname>Katsiougiannis</surname><given-names>S</given-names></name><name><surname>Griffin</surname><given-names>B</given-names></name><name><surname>Votteas</surname><given-names>V</given-names></name><name><surname>Skopouli</surname><given-names>FN</given-names></name></person-group><article-title>Effects of flaxseed oil supplementation on plasma adiponectin levels in dyslipidemic men</article-title><source>Eur J Nutr</source><year>2007</year><volume>46</volume><fpage>315</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1007/s00394-007-0668-5</pub-id><pub-id pub-id-type="pmid">17623225</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoelson</surname><given-names>SE</given-names></name><name><surname>LEE</surname><given-names>J</given-names></name><name><surname>Goldfine</surname><given-names>AB</given-names></name></person-group><article-title>Inflammation and insulin resistance</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>1793</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.1172/JCI29069</pub-id><pub-id pub-id-type="pmid">16823477</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fantuzzi</surname><given-names>G</given-names></name><name><surname>Mazzone</surname><given-names>T</given-names></name></person-group><article-title>Adipose tissue and atherosclerosis. Exploring the connection</article-title><source>Arterioscl Throm Vas</source><year>2007</year><volume>27</volume><fpage>996</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.106.131755</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukumitsu</surname><given-names>S</given-names></name><name><surname>Aida</surname><given-names>K</given-names></name><name><surname>Ueno</surname><given-names>N</given-names></name><name><surname>Ozawa</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Kobori</surname><given-names>M</given-names></name></person-group><article-title>Flaxseed lignan attenuates high fat diet induced fat accumulation and induces adiponectin expression in mice</article-title><source>Brit J Nutr</source><year>2008</year><volume>100</volume><fpage>669</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1017/S0007114508911570</pub-id><pub-id pub-id-type="pmid">18252024</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>MD</given-names></name><name><surname>Ryan</surname><given-names>DH</given-names></name><name><surname>Apovian</surname><given-names>CM</given-names></name><name><surname>Ard</surname><given-names>JD</given-names></name><name><surname>Comuzzie</surname><given-names>AG</given-names></name><name><surname>Donato</surname><given-names>KA</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Hubbard</surname><given-names>VS</given-names></name><name><surname>Jakicic</surname><given-names>JM</given-names></name><name><surname>Kushner</surname><given-names>RF</given-names></name><name><surname>Loria</surname><given-names>CM</given-names></name><name><surname>Millen</surname><given-names>BE</given-names></name><name><surname>Nonas</surname><given-names>CA</given-names></name><name><surname>Pi-Sunyer</surname><given-names>FX</given-names></name><name><surname>Stevens</surname><given-names>J</given-names></name><name><surname>Stevens</surname><given-names>VJ</given-names></name><name><surname>Wadden</surname><given-names>TA</given-names></name><name><surname>Wolfe</surname><given-names>BM</given-names></name><name><surname>Yanovski</surname><given-names>SZ</given-names></name></person-group><article-title>2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society</article-title><source>Circulation</source><year>2014</year><volume>129</volume><issue>25 Suppl 2</issue><fpage>S102</fpage><lpage>S138</lpage><pub-id pub-id-type="doi">10.1161/01.cir.0000437739.71477.ee</pub-id><pub-id pub-id-type="pmid">24222017</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matarese</surname><given-names>LE</given-names></name><name><surname>Pories</surname><given-names>WJ</given-names></name></person-group><article-title>Adult weight loss diets: metabolic effects and outcomes</article-title><source>Nutr Clin Pract</source><year>2014</year><volume>29</volume><fpage>759</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1177/0884533614550251</pub-id><pub-id pub-id-type="pmid">25293593</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esmaillzadeh</surname><given-names>A</given-names></name><name><surname>Mirmiran</surname><given-names>P</given-names></name><name><surname>Azizi</surname><given-names>F</given-names></name></person-group><article-title>Whole grain intake and the prevalence of hypertriglyceridemic waist phenotype in tehranian adults</article-title><source>Am J Clin Nutr</source><year>2005</year><volume>81</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">15640460</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esmaillzadeh</surname><given-names>A</given-names></name><name><surname>Kimiagar</surname><given-names>M</given-names></name><name><surname>Mehrabi</surname><given-names>Y</given-names></name><name><surname>Azadbakht</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name></person-group><article-title>Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome</article-title><source>Am J Clin Nutr</source><year>2006</year><volume>84</volume><fpage>1489</fpage><lpage>1497</lpage><pub-id pub-id-type="pmid">17158434</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemieux</surname><given-names>I</given-names></name><name><surname>Pascot</surname><given-names>A</given-names></name><name><surname>Prud'homme</surname><given-names>D</given-names></name><name><surname>Alm&#x000e9;ras</surname><given-names>N</given-names></name><name><surname>Bogaty</surname><given-names>P</given-names></name><name><surname>Nadeau</surname><given-names>A</given-names></name><name><surname>Bergeron</surname><given-names>J</given-names></name><name><surname>Despr&#x000e9;s</surname><given-names>JP</given-names></name></person-group><article-title>Elevated C-reactive protein. Another component of the aterosthrombotic profile of abdominal obesity</article-title><source>Arterioscl Throm Vas</source><year>2001</year><volume>21</volume><fpage>961</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.21.6.961</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kris-etherton</surname><given-names>PM</given-names></name><name><surname>Harris</surname><given-names>WS</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name></person-group><article-title>Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease</article-title><source>Circulation</source><year>2002</year><volume>106</volume><fpage>2747</fpage><lpage>2757</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000038493.65177.94</pub-id><pub-id pub-id-type="pmid">12438303</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloendon</surname><given-names>LT</given-names></name><name><surname>Balikai</surname><given-names>S</given-names></name><name><surname>Chittams</surname><given-names>J</given-names></name><name><surname>Cunnane</surname><given-names>SC</given-names></name><name><surname>Berlin</surname><given-names>JA</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Szapary</surname><given-names>OP</given-names></name></person-group><article-title>Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial</article-title><source>J Am Coll Nutr</source><year>2008</year><volume>27</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1080/07315724.2008.10719676</pub-id><pub-id pub-id-type="pmid">18460483</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">IDF: <italic>International Diabetes Federation: The IDF Consensus Worldwide Definition of the Metabolic Syndrome</italic>.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Obesity: Presenting and Managing the Goal Epidemic. Report of a WHO Consulation on Obesity</source><year>1998</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</collab></person-group><article-title>Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)</article-title><source>JAMA</source><year>2001</year><volume>285</volume><fpage>2486</fpage><lpage>2497</lpage><pub-id pub-id-type="doi">10.1001/jama.285.19.2486</pub-id><pub-id pub-id-type="pmid">11368702</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chobanian</surname><given-names>AV</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Cushman</surname><given-names>WC</given-names></name><name><surname>Green</surname><given-names>LA</given-names></name><name><surname>Izzo</surname><given-names>JL</given-names></name><name><surname>Jones</surname><given-names>DW</given-names><suffix>Jr</suffix></name><name><surname>Materson</surname><given-names>BJ</given-names></name><name><surname>Oparil</surname><given-names>S</given-names></name><name><surname>Wright</surname><given-names>JT</given-names></name><name><surname>Roccella</surname><given-names>EJ</given-names><suffix>Jr</suffix></name></person-group><article-title>Seventh report of the joint national committee on: prevention, detection, evaluation, and treatment of high blood pressure</article-title><source>Hypertension</source><year>2003</year><volume>42</volume><fpage>1206</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000107251.49515.c2</pub-id><pub-id pub-id-type="pmid">14656957</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicoletti</surname><given-names>CF</given-names></name><name><surname>Camelo</surname><given-names>JS</given-names><suffix>Jr</suffix></name><name><surname>dos Santos</surname><given-names>JE</given-names></name><name><surname>Marchini</surname><given-names>JS</given-names></name><name><surname>Salgado</surname><given-names>W</given-names><suffix>Jr</suffix></name><name><surname>Nonino</surname><given-names>CB</given-names></name></person-group><article-title>Bioelectrical impedance vector analysis in obese women before and after bariatric surgery: changes in body composition</article-title><source>Nutrition</source><year>2014</year><volume>30</volume><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2013.10.013</pub-id><pub-id pub-id-type="pmid">24698348</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>NHANES III</collab></person-group><source>National Health and Nutrition Examination Survey. National Center for Health Statistics</source><year>2009</year></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mion</surname><given-names>D</given-names><suffix>Jr</suffix></name><name><surname>Gomes</surname><given-names>MAM</given-names></name><name><surname>Nobre</surname><given-names>F</given-names></name><name><surname>Amodeo</surname><given-names>C</given-names></name><name><surname>Kohlmann</surname><given-names>O</given-names><suffix>Jr</suffix></name><name><surname>Praxedes</surname><given-names>JN</given-names></name><name><surname>Machado</surname><given-names>CA</given-names></name></person-group><article-title>IV Brazilian guidelines on hypertension</article-title><source>Arq Bra Cardiol</source><year>2004</year><volume>82</volume><issue>2</issue><fpage>15</fpage><lpage>22</lpage></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedewald</surname><given-names>WT</given-names></name><name><surname>Levy</surname><given-names>RI</given-names></name><name><surname>Fredrickson</surname><given-names>DS</given-names></name></person-group><article-title>Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge</article-title><source>Clin Chem</source><year>1972</year><volume>18</volume><fpage>499</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">4337382</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasques</surname><given-names>ACJ</given-names></name></person-group><article-title>An&#x000e1;lise cr&#x000ed;tica do uso dos &#x000ed;ndices do homa na avalia&#x000e7;&#x000e3;o da rersistencia &#x000e0; insulina e capacidade funcional das celulas &#x02013;&#x003b2; pancer&#x000e1;ticas</article-title><source>Arq Bras Endocrinol</source><year>2008</year><volume>2</volume><fpage>52</fpage><lpage>61</lpage></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallund</surname><given-names>J</given-names></name><name><surname>Tetens</surname><given-names>I</given-names></name><name><surname>Bugel</surname><given-names>S</given-names></name><name><surname>Tholstrup</surname><given-names>T</given-names></name><name><surname>Bruun</surname><given-names>JM</given-names></name></person-group><article-title>The effect of a lignan complex isolated from flaxseed on inflammation markers in healthy postmenopausal women</article-title><source>Nutr Metab Cardiovas</source><year>2008</year><volume>18</volume><fpage>497</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2007.05.007</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>A</given-names></name><name><surname>Wahnefried</surname><given-names>WD</given-names></name><name><surname>Xingwang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Qi</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name></person-group><article-title>Effects of a flaxseed derived lignan supplement on C-reactive protein, IL-6 and retinol binding protein 4 in type 2 diabetic patients</article-title><source>Brit J Nutr</source><year>2008</year><volume>74</volume><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>K</given-names></name></person-group><article-title>Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed</article-title><source>Atherosclerosis</source><year>2005</year><volume>179</volume><fpage>269</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2004.11.012</pub-id><pub-id pub-id-type="pmid">15777541</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname><given-names>ICW</given-names></name><name><surname>Hollman</surname><given-names>PCH</given-names></name></person-group><article-title>Polyphenols and disease risk in epidemiologic studies</article-title><source>Am J Clin Nutr</source><year>2005</year><volume>81</volume><fpage>317S</fpage><lpage>325S</lpage><pub-id pub-id-type="pmid">15640497</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kivel&#x000e3;</surname><given-names>AM</given-names></name><name><surname>Kansanen</surname><given-names>E</given-names></name><name><surname>Jyrkk&#x000e2;nen</surname><given-names>HK</given-names></name><name><surname>Nurmi</surname><given-names>T</given-names></name><name><surname>Yl&#x000e3;-herttuala</surname><given-names>S</given-names></name><name><surname>Levonen</surname><given-names>AL</given-names></name></person-group><article-title>Enterolactone induces heme oxygenase-1 expression trough nuclear factor E2 related factor 2 activation in endothelial cells</article-title><source>J Nutr</source><year>2008</year><volume>138</volume><fpage>1263</fpage><lpage>1268</lpage><pub-id pub-id-type="pmid">18567745</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dandona</surname><given-names>P</given-names></name><name><surname>Aljada</surname><given-names>A</given-names></name><name><surname>Bandyopadhyay</surname><given-names>A</given-names></name></person-group><article-title>Inflammation: the link between insulin resistance, obesity and diabetes</article-title><source>Trends Immunol</source><year>2004</year><volume>25</volume><fpage>4</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.it.2003.10.013</pub-id><pub-id pub-id-type="pmid">14698276</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radulian</surname><given-names>G</given-names></name><name><surname>Rusu</surname><given-names>E</given-names></name><name><surname>Dragomir</surname><given-names>AD</given-names></name><name><surname>Posea</surname><given-names>M</given-names></name></person-group><article-title>Metabolic effects of low glycaemic index diets</article-title><source>Nutr J</source><year>2009</year><volume>8</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/1475-2891-8-5</pub-id><pub-id pub-id-type="pmid">19149876</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madsen</surname><given-names>EL</given-names></name><name><surname>Rissanen</surname><given-names>A</given-names></name><name><surname>Bruun</surname><given-names>JM</given-names></name><name><surname>Skogstrand</surname><given-names>K</given-names></name><name><surname>Tonstad</surname><given-names>S</given-names></name><name><surname>Hougaard</surname><given-names>DM</given-names></name><name><surname>Richelsen</surname><given-names>B</given-names></name></person-group><article-title>Weight loss larger than 10% is neede for general improvement of levels of circulation adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study</article-title><source>Euro J Endocrinol</source><year>2008</year><volume>158</volume><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1530/EJE-07-0721</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redman</surname><given-names>LM</given-names></name><name><surname>Heilbronn</surname><given-names>LK</given-names></name><name><surname>Martin</surname><given-names>CK</given-names></name><name><surname>Jonge</surname><given-names>L</given-names></name><name><surname>Williamson</surname><given-names>DA</given-names></name><name><surname>Delany</surname><given-names>JP</given-names></name><name><surname>Ravussin</surname><given-names>E</given-names></name></person-group><article-title>Metabolic and behavioral compensations in response to caloric restriction: Implications for the maintenance of weight loss</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e4377</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0004377</pub-id><pub-id pub-id-type="pmid">19198647</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guimar&#x000e3;es</surname><given-names>ICB</given-names></name><name><surname>de Almeida</surname><given-names>A</given-names></name><name><surname>Santos</surname><given-names>AS</given-names></name><name><surname>Barbosa</surname><given-names>DBV</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>AC</given-names></name></person-group><article-title>Press&#x000e3;o arterial: efeito do &#x000ed;ndice de massa corporal e da circunfer&#x000ea;ncia abdominal em adolescentes</article-title><source>Arq Bras Cardiol</source><year>2008</year><volume>90</volume><fpage>426</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1590/S0066-782X2008000600007</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>VJ</given-names></name><name><surname>Obarzanek</surname><given-names>E</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name><name><surname>Lee</surname><given-names>IM</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Smith West</surname><given-names>D</given-names></name><name><surname>Milas</surname><given-names>C</given-names></name><name><surname>Mattfeldt-Beman</surname><given-names>M</given-names></name><name><surname>Belden</surname><given-names>L</given-names></name><name><surname>Bragg</surname><given-names>C</given-names></name><name><surname>Millstone</surname><given-names>M</given-names></name><name><surname>Raczynski</surname><given-names>J</given-names></name><name><surname>Brewer</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II</article-title><source>Ann Intern Med</source><year>2001</year><volume>134</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-134-1-200101020-00007</pub-id><pub-id pub-id-type="pmid">11187414</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Demark-Wahnefried</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name></person-group><article-title>Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial</article-title><source>PLoS One</source><year>2007</year><volume>2</volume><fpage>e1148</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0001148</pub-id><pub-id pub-id-type="pmid">17987126</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassett</surname><given-names>CM</given-names></name><name><surname>Rodriguez-Leyva</surname><given-names>D</given-names></name><name><surname>Pierce</surname><given-names>GN</given-names></name></person-group><article-title>Experimental and clinical research findings on the cardiovascular benefits of consuming flaxseed</article-title><source>Appl Physiol Nutr Me</source><year>2009</year><volume>34</volume><fpage>965</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1139/H09-087</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prim</surname><given-names>CR</given-names></name><name><surname>Baroncini</surname><given-names>LAV</given-names></name><name><surname>Pr&#x000e9;coma</surname><given-names>LB</given-names></name><name><surname>Caron</surname><given-names>PHL</given-names></name><name><surname>Winter</surname><given-names>G</given-names></name><name><surname>Poletti</surname><given-names>MO</given-names></name><name><surname>Pr&#x000e9;coma</surname><given-names>DB</given-names></name></person-group><article-title>Effects of linseed consumption for a short period of time on lipid profile and atherosclerotic lesions in rabbits fed a hypercholesterolaemic diet</article-title><source>Brit J Nutr</source><year>2012</year><volume>107</volume><fpage>660</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1017/S0007114511003539</pub-id><pub-id pub-id-type="pmid">21791166</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>WS</given-names></name></person-group><article-title>n-3 fatty acids and serum lipoproteins: human studies</article-title><source>Am J Clin Nutr</source><year>1997</year><volume>65</volume><fpage>1645S</fpage><lpage>1654S</lpage><pub-id pub-id-type="pmid">9129504</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kontogianni</surname><given-names>MD</given-names></name><name><surname>Vlassopoulos</surname><given-names>A</given-names></name><name><surname>Gatzieva</surname><given-names>A</given-names></name><name><surname>Farmaki</surname><given-names>AE</given-names></name><name><surname>Katsiougiannis</surname><given-names>S</given-names></name><name><surname>Panagiotakos</surname><given-names>DB</given-names></name><name><surname>Kalogeropoulos</surname><given-names>N</given-names></name><name><surname>Skopouli</surname><given-names>F</given-names></name></person-group><article-title>Flaxseed oil does not affect inflamatory markes and lipid profile compared to olive, in young, healthy, normal weight adults</article-title><source>Metabolism</source><year>2013</year><volume>62</volume><fpage>686</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2012.11.007</pub-id><pub-id pub-id-type="pmid">23347535</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balk</surname><given-names>EM</given-names></name><name><surname>Lichtenstein</surname><given-names>AH</given-names></name><name><surname>Chung</surname><given-names>M</given-names></name><name><surname>Kupelnick</surname><given-names>B</given-names></name><name><surname>Chew</surname><given-names>P</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name></person-group><article-title>Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review</article-title><source>Atherosclerosis</source><year>2006</year><volume>189</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2006.02.012</pub-id><pub-id pub-id-type="pmid">16530201</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jump</surname><given-names>DB</given-names></name><name><surname>Depner</surname><given-names>CM</given-names></name><name><surname>Tripathy</surname><given-names>S</given-names></name></person-group><article-title>Omega-3 fatty acid supplementation and cardiovascular disease</article-title><source>J Lipid Res</source><year>2012</year><volume>53</volume><fpage>2525</fpage><lpage>2545</lpage><pub-id pub-id-type="doi">10.1194/jlr.R027904</pub-id><pub-id pub-id-type="pmid">22904344</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>RD</given-names></name><name><surname>Gagliardi</surname><given-names>ACM</given-names></name><name><surname>Xavier</surname><given-names>HT</given-names></name><name><surname>Magnoni</surname><given-names>CD</given-names></name><name><surname>Cassani</surname><given-names>R</given-names></name><name><surname>Lottenberg</surname><given-names>AM</given-names></name></person-group><article-title>Sociedade brasileira de cardiologia. I diretriz sobre o consumo de gorduras e sa&#x000fa;de cardiovascular</article-title><source>Arq Bras Cardiol</source><year>2013</year><volume>100</volume><fpage>1</fpage><lpage>40</lpage></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanharanta</surname><given-names>M</given-names></name><name><surname>Voutilainen</surname><given-names>S</given-names></name><name><surname>Nurmi</surname><given-names>T</given-names></name><name><surname>Kaikkonen</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>LJ</given-names></name><name><surname>Morrow</surname><given-names>JD</given-names></name><name><surname>Adlercreutz</surname><given-names>H</given-names></name><name><surname>Salonen</surname><given-names>JT</given-names></name></person-group><article-title>Association between low serum enterolactone and increased plasma f2-isoprostanes, a measure of lipid peroxidation</article-title><source>Atherosclerosis</source><year>2002</year><volume>160</volume><fpage>465</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/S0021-9150(01)00603-7</pub-id><pub-id pub-id-type="pmid">11849672</pub-id></element-citation></ref></ref-list></back></article>